David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial.
The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage.
This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address.
A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 08:13Selina Olwanda Ogweno: Expanding Access to Sickle Cell Care for Children and Young People
-
Sep 13, 2026, 08:02Alexandra Rickard: One Donation Can Make All the Difference
-
Sep 13, 2026, 07:41Global Study Defines ISTH BAT Reference Ranges in Children and Adolescents – JTH
-
Sep 13, 2026, 07:1010 Posts Not to Miss This Week
-
Sep 13, 2026, 07:04Mohamed Abdelhadi: Sharing Our Latest Publication
-
Sep 13, 2026, 05:36Speaking Up When Women’s Health Concerns Are Dismissed – Haemophilia Foundation Australia
-
Sep 13, 2026, 05:16W. Alberto Sifuentes Giraldo: Dual Targeted Therapy Shows Promise in Refractory Systemic Autoinflammatory Diseases
-
Sep 13, 2026, 04:42Christopher Robinson: Early Pregnancy Oxylipins May Signal Risk of Fetal Growth Restriction
-
Sep 13, 2026, 04:22Gabriela Hobbs: 2026 Society of Hematologic Oncology Meeting